LEPU BIO Shares Surge Over 4% as CMG901 Clinical Trial Results Selected for Late-Breaking Abstract and to Be Presented at Presidential Symposium

Stock News

Sep 28

LEPU BIO (02157) shares rose over 4%, reaching 3.56% higher at HK$3.935 as of press time, with a trading turnover of HK$11.9371 million.

On the news front, LEPU BIO (02157) announced that at the European Society for Medical Oncology Annual Congress 2026 (2026 ESMO Congress): positive results from the Phase III clinical trial of CMG901 for second-line and later-line (2L+) Claudin 18.2-positive advanced/metastatic gastroesophageal cancer (GEC) have been selected as a Late-Breaking Abstract (LBA) and will be presented as a proffered paper at the Presidential Symposium; positive results from the Phase I clinical study of MRG007, a potential best-in-class CDH17-targeting antibody-drug conjugate (ADC) candidate for the treatment of colorectal cancer (CRC), have been selected as an LBA and will be presented as a rapid oral presentation at the congress.

Positive results from the European Phase II study of the combination therapy of MRG003 and HX008 for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) have been selected for a rapid oral presentation; and positive results from the Phase II study of the combination therapy of MRG003 and HX008 for the treatment of epidermal growth factor receptor-positive (EGFR-positive) unresectable anaplastic/poorly differentiated thyroid cancer have been selected for a rapid oral presentation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/news/1175553010"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1175553010\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1175553010?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-28 09:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175553010","market":"hk","top_or_hot":-1,"title":"LEPU BIO Shares Surge Over 4% as CMG901 Clinical Trial Results Selected for Late-Breaking Abstract and to Be Presented at Presidential Symposium","media":"Stock News","content":"<p>LEPU BIO (02157) shares rose over 4%, reaching 3.56% higher at HK$3.935 as of press time, with a trading turnover of HK$11.9371 million.<br><br>On the news front, <b>LEPU BIO</b> (<b>02157</b>) announced that at the European Society for Medical Oncology Annual Congress 2026 (2026 ESMO Congress): positive results from the Phase III clinical trial of CMG901 for second-line and later-line (2L+) Claudin 18.2-positive advanced/metastatic gastroesophageal cancer (GEC) have been selected as a Late-Breaking Abstract (LBA) and will be presented as a proffered paper at the Presidential Symposium; positive results from the Phase I clinical study of MRG007, a potential best-in-class CDH17-targeting antibody-drug conjugate (ADC) candidate for the treatment of colorectal cancer (CRC), have been selected as an LBA and will be presented as a rapid oral presentation at the congress.<br><br>Positive results from the European Phase II study of the combination therapy of MRG003 and HX008 for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) have been selected for a rapid oral presentation; and positive results from the Phase II study of the combination therapy of MRG003 and HX008 for the treatment of epidermal growth factor receptor-positive (EGFR-positive) unresectable anaplastic/poorly differentiated thyroid cancer have been selected for a rapid oral presentation.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEPU BIO Shares Surge Over 4% as CMG901 Clinical Trial Results Selected for Late-Breaking Abstract and to Be Presented at Presidential Symposium</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEPU BIO Shares Surge Over 4% as CMG901 Clinical Trial Results Selected for Late-Breaking Abstract and to Be Presented at Presidential Symposium\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-28 09:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LEPU BIO (02157) shares rose over 4%, reaching 3.56% higher at HK$3.935 as of press time, with a trading turnover of HK$11.9371 million.<br><br>On the news front, <b>LEPU BIO</b> (<b>02157</b>) announced that at the European Society for Medical Oncology Annual Congress 2026 (2026 ESMO Congress): positive results from the Phase III clinical trial of CMG901 for second-line and later-line (2L+) Claudin 18.2-positive advanced/metastatic gastroesophageal cancer (GEC) have been selected as a Late-Breaking Abstract (LBA) and will be presented as a proffered paper at the Presidential Symposium; positive results from the Phase I clinical study of MRG007, a potential best-in-class CDH17-targeting antibody-drug conjugate (ADC) candidate for the treatment of colorectal cancer (CRC), have been selected as an LBA and will be presented as a rapid oral presentation at the congress.<br><br>Positive results from the European Phase II study of the combination therapy of MRG003 and HX008 for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) have been selected for a rapid oral presentation; and positive results from the Phase II study of the combination therapy of MRG003 and HX008 for the treatment of epidermal growth factor receptor-positive (EGFR-positive) unresectable anaplastic/poorly differentiated thyroid cancer have been selected for a rapid oral presentation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KCAI","symbol_name":"KraneShares China Alpha Index ETF","start_time":0,"source_url":"","article_id":"1175553010","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175553010","pubTimestamp":1790560573,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LEPU BIO (02157) shares rose over 4%, reaching 3.56% higher at HK$3.935 as of press time, with a trading turnover of HK$11.9371 million.On the news front, LEPU BIO (02157) announced that at the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KCAI":"KraneShares China Alpha Index ETF","VXUS":"国际股票ETF-Vanguard","02157":"乐普生物","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技"},"translate_title":"CMG901临床试验结果入选最新摘要并将在总统座谈会上发表，乐普生物股价飙升逾4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02157":1,"KCAI":1,"VXUS":1},"content_text":"LEPU BIO (02157) shares rose over 4%, reaching 3.56% higher at HK$3.935 as of press time, with a trading turnover of HK$11.9371 million.On the news front, LEPU BIO (02157) announced that at the European Society for Medical Oncology Annual Congress 2026 (2026 ESMO Congress): positive results from the Phase III clinical trial of CMG901 for second-line and later-line (2L+) Claudin 18.2-positive advanced/metastatic gastroesophageal cancer (GEC) have been selected as a Late-Breaking Abstract (LBA) and will be presented as a proffered paper at the Presidential Symposium; positive results from the Phase I clinical study of MRG007, a potential best-in-class CDH17-targeting antibody-drug conjugate (ADC) candidate for the treatment of colorectal cancer (CRC), have been selected as an LBA and will be presented as a rapid oral presentation at the congress.Positive results from the European Phase II study of the combination therapy of MRG003 and HX008 for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) have been selected for a rapid oral presentation; and positive results from the Phase II study of the combination therapy of MRG003 and HX008 for the treatment of epidermal growth factor receptor-positive (EGFR-positive) unresectable anaplastic/poorly differentiated thyroid cancer have been selected for a rapid oral presentation.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}